REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS FOR RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) AND MONOCLONAL ANTIBODIES (MAB) THERAPIES

被引：0
|
作者：
Feng, C. [1 ]
Murphy, L. [2 ]
Engel-Nitz, N. [2 ]
Nguyen, A. [2 ]
Patel, A. [1 ]
DuCharme, M. [2 ]
Fu, C. [1 ]
Shah, G. [3 ]
机构：
[1] Kite Pharma, Santa Monica, CA USA
[2] Optum, Eden Prairie, MN USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD178
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [41] Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
    Lin, John K.
    Muffly, Lori S.
    Spinner, Michael A.
    Barnes, James, I
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (24) : 2105 - +
  • [42] REAL-WORLD TREATMENT PATTERNS AND COSTS IN RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
    Mutebi, A.
    Jun, M.
    Flores, C.
    Wang, Z.
    Wang, A.
    Elliot, B.
    Navarro, F. R.
    Kalsekar, A.
    VALUE IN HEALTH, 2022, 25 (07) : S394 - S394
  • [43] Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study
    Tun, Aung M.
    Patel, Romil
    St-Pierre, Frederique
    Ouchveridze, Evguenia
    Niu, Alex
    Obasi, Jennifer
    Rosenthal, Allison C.
    Pophali, Priyanka A.
    Fenske, Timothy S.
    Karmali, Reem
    Ahmed, Sairah
    Johnston, Patrick B.
    BLOOD, 2023, 142
  • [44] Chimeric Antigen Receptor T-Cell Therapy Treatment Patterns: A Retrospective Cohort Analysis of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in the US
    Seyedin, Roxanna
    Snider, Julia Thornton
    Rajagopalan, Krithika
    Wade, Sally W.
    Gergis, Usama
    BLOOD, 2021, 138
  • [45] Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
    Casadei, Beatrice
    Argnani, Lisa
    Guadagnuolo, Serafina
    Pellegrini, Cinzia
    Stefoni, Vittorio
    Broccoli, Alessandro
    Nanni, Laura
    Morigi, Alice
    Lolli, Ginevra
    Guarino, Maria
    Spinardi, Luca
    Pierucci, Elisabetta
    Fanti, Stefano
    Bartoletti, Michele
    Dicataldo, Michele
    Sabattini, Elena
    Bonifazi, Francesca
    Zinzani, Pier Luigi
    CANCERS, 2021, 13 (19)
  • [46] Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States
    Kilgore, Karl M.
    Chan, Philip K.
    Teigland, Christie
    Wade, Sally W.
    Mohammadi, Iman
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (03): : 262 - 276
  • [47] Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma
    Lutfi, Forat
    Holtzman, Noa
    Siglin, Jonathan
    Bukhari, Ali
    Mustafa Ali, Moaath
    Kim, Dong
    Sanchez-Petitto, Gabriela
    Gottlieb, David
    Ruehle, Kathleen
    Hutnick, Elizabeth
    Gahres, Natalie
    Hankey, Kim
    Lee, Seung
    Kocoglu, Mehmet
    Yared, Jean
    Hardy, Nancy
    Rapoport, Aaron
    Dahiya, Saurabh
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (01) : 212 - 216
  • [48] Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
    Bachanova, Veronika
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph P.
    Holte, Harald
    Waller, Edmund K.
    Jaglowski, Samantha
    Bishop, Michael R.
    Andreadis, Charalambos
    Foley, Stephen Ronan
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles
    Schuster, Stephen J.
    Maziarz, Richard T.
    Van Besien, Koen
    Izutsu, Koji
    Kersten, Marie Jose
    Magenau, John M.
    Wagner-Johnston, Nina D.
    Kato, Koji
    Corradini, Paolo
    Chu, Jufen
    Gershgorin, Irina
    Choquette, Therese
    Pacaud, Lida Bubuteishvili
    Jeschke, Margit
    BLOOD, 2019, 134
  • [49] COST-EFFECTIVENESS ANALYSIS OF AXICABTAGENE CILOLEUCEL, LISOCABTAGENE MARALEUCEL, AND TISAGENLECLEUCEL CAR T-CELL THERAPIES FOR TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)
    Ghanem, B.
    Seoane-Vazquez, E.
    Fleming, M.
    Brown, L. M.
    Rodriguez-Monguio, R.
    VALUE IN HEALTH, 2023, 26 (06) : S75 - S75
  • [50] Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
    Nastoupil, Loretta J.
    Jain, Michael D.
    Spiegel, Jay Y.
    Ghobadi, Armin
    Lin, Yi
    Dahiya, Saurabh
    Lunning, Matthew A.
    Lekakis, Lazaros J.
    Reagan, Patrick M.
    Oluwole, Olalekan O.
    McGuirk, Joseph P.
    Deol, Abhinav
    Sehgal, Alison R.
    Goy, Andre
    Hill, Brian T.
    Andreadis, Charalambos
    Munoz, Javier
    Westin, Jason R.
    Chavez, Julio C.
    Cashen, Amanda F.
    Bennani, Nora N.
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Locke, Frederick L.
    BLOOD, 2018, 132
12345